Crossmark

Sequential and co-occurring DNA damage response genetic mutations impact survival in stage III colorectal cancer patients receiving adjuvant oxaliplatin-based chemotherapy

Crossref DOI link: https://doi.org/10.1186/s12885-021-07926-1

Published Online: 2021-03-02

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lin, Peng-Chan

Yeh, Yu-Min

Chan, Ren-Hao

Lin, Bo-Wen

Chen, Po-Chuan

Pan, Chien-Chang

Shen, Meng-Ru
License Information

Text and Data Mining valid from 2021-03-02

Version of Record valid from 2021-03-02
More Information

Article History

Received: 26 November 2020

Accepted: 17 February 2021

First Online: 2 March 2021

Ethics approval and consent to participate

: This study was approved by the Institutional Review Board of National Cheng Kung University Hospital (A-ER-103-395 and A-ER-104-153) and conducted in accordance with the Declaration of Helsinki. All participants provided written informed consent.

: Not applicable.

: None declared.

Document is current

Any future updates will be listed below